观察中药灌肠与坦索罗辛联合治疗慢性前列腺炎的临床疗效
|
摘要
目的观察中药灌肠与坦索罗辛联合治疗慢性前列腺炎的临床疗效。方法随机选取2015年5月至2017年5月郫都区第二人民医院泌尿科诊治的80例慢性前列腺炎患者,依据治疗方法将其分为坦索罗辛单独治疗组和中药灌肠与坦索罗辛联合治疗组,每组40例患者。对两组患者的慢性前列腺炎症状积分指数(NIH-CPSI)评分、临床疗效进行统计分析。结果联合治疗组患者的尿路症状、疼痛症状、生活质量评分和NIH-CPSI总分均显著低于单独治疗组,其差异均具有统计学意义(均P<0.05);联合治疗组患者的治疗总有效率92.5%(37/40)显著高于单独治疗组患者的70.0%(28/40),其差异具有统计学意义(P<0.05)。结论中药灌肠与坦索罗辛联合治疗慢性前列腺炎的效果优于坦索罗辛单独治疗,值得在临床推广。
Objective To observe the clinical curative effect of traditional Chinese medicine enema combined with tamsulosin in the treatment of chronic prostatitis. Methods 80 patients with chronic prostatitis in Department of Urology of the Second Pidu District People′s Hospital from May 2015 to May 2017 were randomly selected and divided into tamsulosin treatment alone group(alone treatment group, n=40) and traditional Chinese medicine enema and tamsulosin combined treatment group(combined treatment group, n=40) according to the treatment methods. The NIH-CPSI scores and clinical curative effects of the two groups were statistically analyzed. Results The urinary symptoms, pain symptoms, quality of life scores and NIH-CPSI score of the combined treatment group were significantly lower than those in the single treatment group(all P<0.05), and the total treatment efficiency(92.5%, 37/40) was significantly higher than that of the alone treatment group(70.0%, 28/40)(P<0.05). Conclusions The clinical curative effect of traditional Chinese medicine enema and tamsulosin combined treatment is more significant than tamsulosin treatment alone in the treatment of chronic prostatitis.
Objective To observe the clinical curative effect of traditional Chinese medicine enema combined with tamsulosin in the treatment of chronic prostatitis. Methods 80 patients with chronic prostatitis in Department of Urology of the Second Pidu District People′s Hospital from May 2015 to May 2017 were randomly selected and divided into tamsulosin treatment alone group(alone treatment group, n=40) and traditional Chinese medicine enema and tamsulosin combined treatment group(combined treatment group, n=40) according to the treatment methods. The NIH-CPSI scores and clinical curative effects of the two groups were statistically analyzed. Results The urinary symptoms, pain symptoms, quality of life scores and NIH-CPSI score of the combined treatment group were significantly lower than those in the single treatment group(all P<0.05), and the total treatment efficiency(92.5%, 37/40) was significantly higher than that of the alone treatment group(70.0%, 28/40)(P<0.05). Conclusions The clinical curative effect of traditional Chinese medicine enema and tamsulosin combined treatment is more significant than tamsulosin treatment alone in the treatment of chronic prostatitis.
引文
[1] 王省博,卢子杰,苏昀,等.慢性前列腺炎中医外治法研究进展[J].南京中医药大学学报,2014,30(3):297-300.
[2] 叶刚,池建平,李英伦,等.针刺对慢性前列腺炎大鼠组织学及血清中TNF-α和IL-6的影响[J].中国老年学杂志,2014,34(5):1330-1331.
[3] 夏雨果,曾文彤,梅雪峰,等.联合应用郁乐疏合剂治疗慢性前列腺炎的临床疗效评价[J].中华男科学杂志,2014,20(2):177-180.
[4] 郭宏志,刘云波,曾明月,等.补肾活血利湿类中药复方治疗慢性前列腺炎疗效与安全性的系统评价[J].中国药房,2016,27(30):4241-4244.
[5] 王博,史本康.川芎嗪经超声电导前列腺治疗仪直肠给药治疗Ⅲ型慢性前列腺炎效果观察[J].山东医药,2017,57(2):85-86.
[6] 王彬,李海松,高瞻,等.复方玄驹胶囊治疗Ⅲ型慢性前列腺炎(肾虚血瘀证)的多中心临床疗效评价[J].中国男科学杂志,2017,31(2):40-46.
[7] 张毅,林倩,曹丽萍,等.非介入式前列腺超声联合中西药治疗慢性前列腺炎/慢性骨盆疼痛综合征[J].中国生化药物杂志,2017,37(6):109-110,113.
[8] 薛建国,樊千.慢性前列腺炎中医辨治探讨[J].南京中医药大学学报,2014,30(6):504-506.
[9] 赵良运,王田,毛晓鹏,等.慢性前列腺炎患者勃起功能障碍的临床相关性分析[J].中华泌尿外科杂志,2015,36(4):304-306.
[10] 李洁冰,张艳华,杨洪艳,等.慢性前列腺炎及多灶型HGPIN患者再次穿刺时发展为前列腺癌风险的研究[J].实用肿瘤学杂志,2017,31(3):217-221.
[11] 刘伟群,张贤生,汤冬冬,等.不同类型早泄患者早泄诊断工具与慢性前列腺炎症状评分间的相关性分析[J].中国男科学杂志,2017,31(2):14-17,21.
[12] 周萍,肖金海,江琼,等.清热利湿通淋汤联合坦索罗辛治疗慢性前列腺炎湿热下注证的疗效[J].实用医学杂志,2016,32(12):2055-2057.
[13] 郑涛,张亚东,陈鑫,等.UPOINT分类因子对慢性前列腺炎/慢性骨盆疼痛综合征患者勃起功能的影响[J].中山大学学报(医学科学版),2015,36(2):237-240.
[14] 祖宁辉,杨荣华.前列癃闭通片治疗慢性前列腺炎及其患者免疫功能的影响[J].中国性科学,2016,25(1):112-114.
[15] 高筱松,高文喜,贺菊乔,等.前列泌尿栓治疗慢性前列腺炎多中心双盲阳性药对照试验研究[J].中国性科学,2016,25(8):135-138.
[16] Seong KM,Jang G,Kim DW,et al.Hwanglyunhaedok pharmacopuncture versus saline pharmacopuncture on chronic nonbacterial prostatitis/chronic pelvic pain syndrome[J].J Acupunct Meridian Stud,2017,10(4):245-251.
[17] Nunzio C,Giglio S,Stoppacciaro A,et al.Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia[J].Oncotarget,2017,8(31):50904-50910.
[18] He Y,Zeng H,Yu Y,et al.Resveratrol improves smooth muscle carcinogenesis in the progression of chronic prostatitis via the down regulation of c-kit/SCF by activating sirt1[J].Biomed Pharmacother,2017,95(1):161-166.
[2] 叶刚,池建平,李英伦,等.针刺对慢性前列腺炎大鼠组织学及血清中TNF-α和IL-6的影响[J].中国老年学杂志,2014,34(5):1330-1331.
[3] 夏雨果,曾文彤,梅雪峰,等.联合应用郁乐疏合剂治疗慢性前列腺炎的临床疗效评价[J].中华男科学杂志,2014,20(2):177-180.
[4] 郭宏志,刘云波,曾明月,等.补肾活血利湿类中药复方治疗慢性前列腺炎疗效与安全性的系统评价[J].中国药房,2016,27(30):4241-4244.
[5] 王博,史本康.川芎嗪经超声电导前列腺治疗仪直肠给药治疗Ⅲ型慢性前列腺炎效果观察[J].山东医药,2017,57(2):85-86.
[6] 王彬,李海松,高瞻,等.复方玄驹胶囊治疗Ⅲ型慢性前列腺炎(肾虚血瘀证)的多中心临床疗效评价[J].中国男科学杂志,2017,31(2):40-46.
[7] 张毅,林倩,曹丽萍,等.非介入式前列腺超声联合中西药治疗慢性前列腺炎/慢性骨盆疼痛综合征[J].中国生化药物杂志,2017,37(6):109-110,113.
[8] 薛建国,樊千.慢性前列腺炎中医辨治探讨[J].南京中医药大学学报,2014,30(6):504-506.
[9] 赵良运,王田,毛晓鹏,等.慢性前列腺炎患者勃起功能障碍的临床相关性分析[J].中华泌尿外科杂志,2015,36(4):304-306.
[10] 李洁冰,张艳华,杨洪艳,等.慢性前列腺炎及多灶型HGPIN患者再次穿刺时发展为前列腺癌风险的研究[J].实用肿瘤学杂志,2017,31(3):217-221.
[11] 刘伟群,张贤生,汤冬冬,等.不同类型早泄患者早泄诊断工具与慢性前列腺炎症状评分间的相关性分析[J].中国男科学杂志,2017,31(2):14-17,21.
[12] 周萍,肖金海,江琼,等.清热利湿通淋汤联合坦索罗辛治疗慢性前列腺炎湿热下注证的疗效[J].实用医学杂志,2016,32(12):2055-2057.
[13] 郑涛,张亚东,陈鑫,等.UPOINT分类因子对慢性前列腺炎/慢性骨盆疼痛综合征患者勃起功能的影响[J].中山大学学报(医学科学版),2015,36(2):237-240.
[14] 祖宁辉,杨荣华.前列癃闭通片治疗慢性前列腺炎及其患者免疫功能的影响[J].中国性科学,2016,25(1):112-114.
[15] 高筱松,高文喜,贺菊乔,等.前列泌尿栓治疗慢性前列腺炎多中心双盲阳性药对照试验研究[J].中国性科学,2016,25(8):135-138.
[16] Seong KM,Jang G,Kim DW,et al.Hwanglyunhaedok pharmacopuncture versus saline pharmacopuncture on chronic nonbacterial prostatitis/chronic pelvic pain syndrome[J].J Acupunct Meridian Stud,2017,10(4):245-251.
[17] Nunzio C,Giglio S,Stoppacciaro A,et al.Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia[J].Oncotarget,2017,8(31):50904-50910.
[18] He Y,Zeng H,Yu Y,et al.Resveratrol improves smooth muscle carcinogenesis in the progression of chronic prostatitis via the down regulation of c-kit/SCF by activating sirt1[J].Biomed Pharmacother,2017,95(1):161-166.